Equity Profile

RGC

Regencell Bioscience Holdings Limited

Health CarePharmaceuticals$2.6B

Jun27Thu

Pre-Earnings Brief

UpcomingQ4-2017After Close5:00 PM EDT

Company Snapshot

Regencell Bioscience Holdings Limited is a pharmaceutical company focused on developing innovative therapies. Operating in the health care sector, it aims to address significant medical needs, which makes its performance relevant to investors interested in health advancements.

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, falling short of the expected $0.11. This marked a continuation of earnings misses, raising concerns among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance.

Bull Case

If Regencell can show significant improvement in EPS and revenue, it may restore investor confidence and drive the stock price higher.

Bear Case

Conversely, continued earnings misses could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the previous quarter's $0.07?

A positive EPS could signal a turnaround and improve investor confidence.

What is the company's current R&D spending compared to last quarter?

Increased spending could indicate a commitment to innovation, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to recover from its recent earnings misses due to its ongoing R&D efforts.

Supporting Evidence

Despite recent misses, Regencell has a strong pipeline that could lead to future growth.

Options pricing suggests a larger move than historical averages, indicating potential for volatility.

The company's commitment to R&D spending could yield positive results not yet reflected in analyst expectations.

Key Risk

If R&D spending shows significant increases, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Regencell can turn around its recent performance and regain investor trust.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case and suggest recovery.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a potential average move of +3.6%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, leading to minimal movement.

Miss

A miss could lead to a decline, with history suggesting an average move of -1.3% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Management's outlook on future revenue growth.
3Details on cost management strategies.
4Insights into competitive positioning within the pharmaceutical market.
5Any commentary on regulatory challenges or approvals.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Jun25

SNXReported

TD SYNNEX Corporation

RecapView

Jun25

CUKReported

Company Snapshot

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of the company's profitability and is closely watched by investors.

N/A

Revenue Growth

Revenue growth reflects the company's ability to increase sales and expand its market presence.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

RGC Q4-2017 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-3.97%

Avg Stock Reaction

+0.00%

Last Quarter Recap

In the last quarter, Regencell reported an EPS of $0.07, falling short of the expected $0.11. This marked a continuation of earnings misses, raising concerns among investors.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, expectations for Regencell's upcoming earnings are mixed, with uncertainty surrounding its ability to meet or exceed prior performance.

Bull Case

If Regencell can show significant improvement in EPS and revenue, it may restore investor confidence and drive the stock price higher.

Bear Case

Conversely, continued earnings misses could lead to further declines in stock price and investor sentiment.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will EPS exceed the previous quarter's $0.07?

A positive EPS could signal a turnaround and improve investor confidence.

What is the company's current R&D spending compared to last quarter?

Increased spending could indicate a commitment to innovation, which is crucial for future growth.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Regencell to recover from its recent earnings misses due to its ongoing R&D efforts.

Supporting Evidence

Despite recent misses, Regencell has a strong pipeline that could lead to future growth.

Options pricing suggests a larger move than historical averages, indicating potential for volatility.

The company's commitment to R&D spending could yield positive results not yet reflected in analyst expectations.

Key Risk

If R&D spending shows significant increases, it could shift market sentiment positively.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate centers around whether Regencell can turn around its recent performance and regain investor trust.

Bull Confirmed If

An EPS of $0.10 or higher would confirm the bull case and suggest recovery.

Bear Confirmed If

An EPS below $0.05 would confirm the bear case and raise concerns about the company's viability.

Pre-Earnings Positioning

Options Market

Implied Move

±11.9%

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Detail

ATM IV

1.4%

30d HV

69.6%

Calls (5K)P/C Ratio: 0.02Puts (7K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter miss setup in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Regencell beats expectations, history suggests a potential average move of +3.6%, confirming a positive outlook.

In-Line / Cautious

If results are in line with expectations, the stock may react cautiously, leading to minimal movement.

Miss

A miss could lead to a decline, with history suggesting an average move of -1.3% following such outcomes.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new product developments or clinical trials.
2Management's outlook on future revenue growth.
3Details on cost management strategies.
4Insights into competitive positioning within the pharmaceutical market.
5Any commentary on regulatory challenges or approvals.